Related Programs

Error message

  • Deprecated function: Optional parameter $checkbox declared before required parameter $input is implicitly treated as a required parameter in include_once() (line 1439 of /local/drupal/itcr/includes/bootstrap.inc).
  • Deprecated function: Optional parameter $key declared before required parameter $is_multi is implicitly treated as a required parameter in require_once() (line 342 of /local/drupal/itcr/includes/module.inc).
  • Deprecated function: Optional parameter $route declared before required parameter $is_multi is implicitly treated as a required parameter in require_once() (line 342 of /local/drupal/itcr/includes/module.inc).
  • Deprecated function: Return type of crumbs_PluginSystem_PluginMethodIterator::current() should either be compatible with Iterator::current(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 4 of /local/drupal/itcr/sites/all/modules/crumbs/lib/PluginSystem/PluginMethodIterator.php).
  • Deprecated function: Return type of crumbs_PluginSystem_PluginMethodIterator::next() should either be compatible with Iterator::next(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 4 of /local/drupal/itcr/sites/all/modules/crumbs/lib/PluginSystem/PluginMethodIterator.php).
  • Deprecated function: Return type of crumbs_PluginSystem_PluginMethodIterator::key() should either be compatible with Iterator::key(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 4 of /local/drupal/itcr/sites/all/modules/crumbs/lib/PluginSystem/PluginMethodIterator.php).
  • Deprecated function: Return type of crumbs_PluginSystem_PluginMethodIterator::valid() should either be compatible with Iterator::valid(): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 4 of /local/drupal/itcr/sites/all/modules/crumbs/lib/PluginSystem/PluginMethodIterator.php).
  • Deprecated function: Return type of crumbs_PluginSystem_PluginMethodIterator::rewind() should either be compatible with Iterator::rewind(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 4 of /local/drupal/itcr/sites/all/modules/crumbs/lib/PluginSystem/PluginMethodIterator.php).
×

You are here

NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR)

SBIR and STTR programs support early-stage technology financing, mentoring and networking assistance for small businesses with next-generation cancer technologies.

The following programs and funding announcements represent related NCI and NIH programs and collaboration opportunities for ITCR participants.

  • NCI Physical Sciences in Oncology Initiative

    The National Cancer Institute (NCI) is exploring new and innovative scientific approaches to better understand and control cancer. The Division of Cancer Biology’s Physical Sciences in Oncology Initiative seeks to establish research projects that bring together cancer biologists and oncologists with scientists from the fields of physics, mathematics, chemistry, and engineering to address some of the major questions and barriers in cancer research.

    In 2009, the Physical Sciences – Oncology Centers (PS-OCs) Program was launched, a Network of 12 Centers investigating complex and challenging questions in cancer research from a physical sciences perspective. To explore how the NCI could continue to support the integration of physical sciences and cancer research, a Think Tank and series of Strategic Workshops were held in 2012. The workshops served to update opportunities at the interface of physical sciences and cancer research and guide the development of Program Announcements for a second phase of the PS-OC Program and Physical Science – Oncology Projects (PS-OPs) Program that together will form the Physical Sciences – Oncology Network (PS-ON).

  • Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)

    The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science using artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge addressing priority needs across the infectious or immune-mediated disease research continuum.

  • Predictive Multiscale Modeling Program

    The goal of this interagency funding opportunity announcement (FOA) is to support the development of multiscale models to accelerate biological, biomedical, behavioral, environmental and clinical research. The NIH, ARO, DOE, FDA, NASA, NSF, and ONR recognize that in order to efficiently and effectively address the challenges of understanding multiscale biological and behavioral systems, researchers will need predictive, computational models that encompass multiple biological and behavioral scales.  This FOA supports the development of non-standard modeling methods and experimental approaches to facilitate multiscale modeling, and active participation in community-driven activities through the Multiscale Modeling (MSM) Consortium, www.imagwiki.nibib.nih.gov.

  • Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)

    The purpose of this Funding Opportunity Announcement (FOA) is to support early-stage development from prototyping to hardening and adaptation of data science technologies that improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum.

  • Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)

    The purpose of this Funding Opportunity Announcement (FOA) is to support enhancement and/or sustainment of high-value data science research software to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge across the immune-mediated, and infectious-disease research continuum.

  • The NCI Quantitative Imaging Network

    The QIN Imaging Network is designed to promote research and development of quantitative imaging methods for the measurement of tumor response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision-making. The main emphasis is on development of quantitative imaging methods, imaging protocols and software tools as well as application of these methods in current and planned clinical therapy trials.

  • Cancer Systems Biology Consortium

    Cancer is a complex disease system involving multiple molecular, genetic, and cellular events. From its early initiation through progression and metastasis, cancer can adapt and evolve as a result of both internal and external signals. These properties make cancer difficult to predict, prevent, and treat. There has been significant progress in characterizing the genetics of cancer, as well as the downstream effects on the molecular and cellular pathways that are critical for the initiation and progression of cancer.

  • Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes, R01

    This funding opportunity announcement (FOA) encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data.

  • Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes, R21

    This funding opportunity announcement (FOA) encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data.

  • The National Human Genome Research Institute (NHGRI) Computational Genomics and Data Science Program

    Investigator Initiated Research in Computational Genomics and Data Science FOAs invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease.

    PAR-21-254 (R01)

    PAR-21-255 (R21)

  • Biomedical Data Repository

    Biomedical data repositories should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository.

  • Biomedical Knowledgebase

    Biomedical knowledgebases should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase.

  • Exploratory/Developmental Bioengineering Research Grants (BRG)

    The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. 

    PAR-22-090 (R21) 

  • Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment

    The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease.

  • Assay Validation of High Quality Markers for Clinical Studies in Cancer

    This Funding Opportunity Announcement (FOA) is to supports the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. The FOA also includes the validation of pharmacodynamic markers and markers of toxicity. markers, including immune markers, can be developed and validated simultaneously.

  • Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)

    The purpose of this Funding Opportunity Announcement (FOA) is to support proof of concept, high-risk and high-reward studies for feasibility and exploratory technology research leading to the development of innovative technologies for biomedical research.

    The FOA does not support technology development that is narrowly focused on addressing specific biological questions, but rather, development of innovative tools that can potentially benefit a broad spectrum of biomedical research.

  • Focused Technology Research and Development (R01 Clinical Trial Not Allowed)

    The purpose of this Funding Opportunity Announcement (FOA) is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility of biomedical knowledge.

  • NCI Innovative Molecular Analysis Technologies (IMAT) Program

    The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. In support of its mission, the IMAT program utilizes a variety of investigator-initiated research project grant mechanisms while retaining a strong commitment to diversity and to the training of scientists and clinicians in cross-cutting, research-enabling disciplines.

  • NCI SBIR and STTR

    Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs support early-stage technology financing, mentoring and networking assistance for small businesses with next-generation cancer technologies.